vs

Side-by-side financial comparison of Global Medical REIT Inc. (GMRE) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

RIGEL PHARMACEUTICALS INC is the larger business by last-quarter revenue ($69.8M vs $38.4M, roughly 1.8× Global Medical REIT Inc.). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs -16.0%, a 400.0% gap on every dollar of revenue. On growth, RIGEL PHARMACEUTICALS INC posted the faster year-over-year revenue change (21.2% vs 9.2%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 4.6%).

Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

GMRE vs RIGL — Head-to-Head

Bigger by revenue
RIGL
RIGL
1.8× larger
RIGL
$69.8M
$38.4M
GMRE
Growing faster (revenue YoY)
RIGL
RIGL
+12.0% gap
RIGL
21.2%
9.2%
GMRE
Higher net margin
RIGL
RIGL
400.0% more per $
RIGL
384.0%
-16.0%
GMRE
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
4.6%
GMRE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GMRE
GMRE
RIGL
RIGL
Revenue
$38.4M
$69.8M
Net Profit
$-6.1M
$268.1M
Gross Margin
91.5%
Operating Margin
33.2%
Net Margin
-16.0%
384.0%
Revenue YoY
9.2%
21.2%
Net Profit YoY
-309.2%
1769.2%
EPS (diluted)
$-0.48
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GMRE
GMRE
RIGL
RIGL
Q4 25
$38.4M
$69.8M
Q3 25
$37.2M
$69.5M
Q2 25
$38.0M
$101.7M
Q1 25
$34.6M
$53.3M
Q4 24
$35.2M
$57.6M
Q3 24
$34.3M
$55.3M
Q2 24
$34.2M
$36.8M
Q1 24
$35.1M
$29.5M
Net Profit
GMRE
GMRE
RIGL
RIGL
Q4 25
$-6.1M
$268.1M
Q3 25
$-5.1M
$27.9M
Q2 25
$585.0K
$59.6M
Q1 25
$3.7M
$11.4M
Q4 24
$2.9M
$14.3M
Q3 24
$3.4M
$12.4M
Q2 24
$-2.0M
$-1.0M
Q1 24
$2.3M
$-8.2M
Gross Margin
GMRE
GMRE
RIGL
RIGL
Q4 25
91.5%
Q3 25
93.2%
Q2 25
95.6%
Q1 25
91.7%
Q4 24
89.9%
Q3 24
85.5%
Q2 24
92.4%
Q1 24
93.1%
Operating Margin
GMRE
GMRE
RIGL
RIGL
Q4 25
33.2%
Q3 25
40.9%
Q2 25
60.1%
Q1 25
23.9%
Q4 24
28.9%
Q3 24
25.4%
Q2 24
1.2%
Q1 24
-23.6%
Net Margin
GMRE
GMRE
RIGL
RIGL
Q4 25
-16.0%
384.0%
Q3 25
-13.6%
40.2%
Q2 25
1.5%
58.6%
Q1 25
10.8%
21.5%
Q4 24
8.4%
24.9%
Q3 24
9.9%
22.5%
Q2 24
-5.7%
-2.8%
Q1 24
6.6%
-27.9%
EPS (diluted)
GMRE
GMRE
RIGL
RIGL
Q4 25
$-0.48
$14.11
Q3 25
$-0.45
$1.46
Q2 25
$-0.01
$3.28
Q1 25
$0.03
$0.63
Q4 24
$-0.04
$0.82
Q3 24
$0.14
$0.70
Q2 24
$-0.05
$-0.06
Q1 24
$0.01
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GMRE
GMRE
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$9.1M
$155.0M
Total DebtLower is stronger
$1.2M
$52.5M
Stockholders' EquityBook value
$509.8M
$391.5M
Total Assets
$1.2B
$513.6M
Debt / EquityLower = less leverage
0.00×
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GMRE
GMRE
RIGL
RIGL
Q4 25
$9.1M
$155.0M
Q3 25
$7.1M
$137.1M
Q2 25
$6.6M
$108.4M
Q1 25
$5.4M
$77.1M
Q4 24
$6.8M
$77.3M
Q3 24
$5.7M
$61.1M
Q2 24
$5.0M
$49.1M
Q1 24
$1.3M
$49.5M
Total Debt
GMRE
GMRE
RIGL
RIGL
Q4 25
$1.2M
$52.5M
Q3 25
$1.2M
$60.0M
Q2 25
$14.2M
$60.0M
Q1 25
$14.3M
$60.0M
Q4 24
$14.4M
$60.0M
Q3 24
$14.5M
$60.0M
Q2 24
$14.7M
$60.0M
Q1 24
$25.7M
$60.0M
Stockholders' Equity
GMRE
GMRE
RIGL
RIGL
Q4 25
$509.8M
$391.5M
Q3 25
$485.3M
$117.6M
Q2 25
$503.2M
$81.9M
Q1 25
$517.4M
$18.6M
Q4 24
$534.1M
$3.3M
Q3 24
$542.6M
$-14.6M
Q2 24
$556.4M
$-29.9M
Q1 24
$575.0M
$-31.7M
Total Assets
GMRE
GMRE
RIGL
RIGL
Q4 25
$1.2B
$513.6M
Q3 25
$1.3B
$242.5M
Q2 25
$1.3B
$206.7M
Q1 25
$1.3B
$176.0M
Q4 24
$1.3B
$164.0M
Q3 24
$1.2B
$139.4M
Q2 24
$1.2B
$128.4M
Q1 24
$1.3B
$126.5M
Debt / Equity
GMRE
GMRE
RIGL
RIGL
Q4 25
0.00×
0.13×
Q3 25
0.00×
0.51×
Q2 25
0.03×
0.73×
Q1 25
0.03×
3.23×
Q4 24
0.03×
18.25×
Q3 24
0.03×
Q2 24
0.03×
Q1 24
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GMRE
GMRE
RIGL
RIGL
Operating Cash FlowLast quarter
$73.6M
$22.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GMRE
GMRE
RIGL
RIGL
Q4 25
$73.6M
$22.0M
Q3 25
$17.6M
$24.0M
Q2 25
$22.1M
$30.5M
Q1 25
$12.3M
$-893.0K
Q4 24
$70.0M
$14.5M
Q3 24
$16.3M
$21.7M
Q2 24
$18.9M
$302.0K
Q1 24
$14.3M
$-5.0M
Cash Conversion
GMRE
GMRE
RIGL
RIGL
Q4 25
0.08×
Q3 25
0.86×
Q2 25
37.84×
0.51×
Q1 25
3.28×
-0.08×
Q4 24
23.83×
1.01×
Q3 24
4.81×
1.75×
Q2 24
Q1 24
6.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons